Patent application number | Description | Published |
20080312278 | Hydroxyquinoline Derivatives - Compounds of the formula I in which X, Y, R | 12-18-2008 |
20090035270 | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha - The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone. | 02-05-2009 |
20090130098 | Specific therapy using integrin ligands for treating cancer - The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered consecutively with said ligands, such as chemotherapeutic agents and or radiation therapy. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone, concurrently or not in the dosage regime of the present invention. | 05-21-2009 |
20090163556 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS - The present invention relates to glycinamide derivatives of formula I, | 06-25-2009 |
20090253688 | Semicarbazide derivatives as kinase inhibitors - The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 10-08-2009 |
20090298885 | METHYLENE UREA DERIVATIVES - The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 12-03-2009 |
20110165150 | Isolated organ perfusion combination therapy of cancer - The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of integrin ligands, preferably integrin antagonists, together with co-therapeutic agents or therapy forms that have synergistic efficacy when administered together with said ligands, such as chemotherapeutic agents and/or radiation therapy, in isolated organ perfusion. The therapy results in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone. | 07-07-2011 |
20110177027 | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha - The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone. | 07-21-2011 |
20130158076 | Methylene Urea Derivatives - The present invention relates to methylene urea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 06-20-2013 |